{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:05:28Z","timestamp":1776747928277,"version":"3.51.2"},"reference-count":155,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UIDB\/00674\/2020"],"award-info":[{"award-number":["UIDB\/00674\/2020"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UIDP\/00674\/2020"],"award-info":[{"award-number":["UIDP\/00674\/2020"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["M1420-01-0145-FEDER-000005"],"award-info":[{"award-number":["M1420-01-0145-FEDER-000005"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["M1420-09-5369-FSE-000001"],"award-info":[{"award-number":["M1420-09-5369-FSE-000001"]}]},{"name":"FCT-Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["UIDB\/00674\/2020"],"award-info":[{"award-number":["UIDB\/00674\/2020"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["UIDP\/00674\/2020"],"award-info":[{"award-number":["UIDP\/00674\/2020"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["M1420-01-0145-FEDER-000005"],"award-info":[{"award-number":["M1420-01-0145-FEDER-000005"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["M1420-09-5369-FSE-000001"],"award-info":[{"award-number":["M1420-09-5369-FSE-000001"]}]},{"name":"ARDITI-Ag\u00eancia Regional para o Desenvolvimento da Investiga\u00e7\u00e3o Tecnologia e Inova\u00e7\u00e3o","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]},{"name":"ARDITI","award":["UIDB\/00674\/2020"],"award-info":[{"award-number":["UIDB\/00674\/2020"]}]},{"name":"ARDITI","award":["UIDP\/00674\/2020"],"award-info":[{"award-number":["UIDP\/00674\/2020"]}]},{"name":"ARDITI","award":["M1420-01-0145-FEDER-000005"],"award-info":[{"award-number":["M1420-01-0145-FEDER-000005"]}]},{"name":"ARDITI","award":["M1420-09-5369-FSE-000001"],"award-info":[{"award-number":["M1420-09-5369-FSE-000001"]}]},{"name":"ARDITI","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]},{"name":"N\u00facleo Regional da Madeira da Liga Portuguesa contra o Cancro (LPCC-NRM)","award":["UIDB\/00674\/2020"],"award-info":[{"award-number":["UIDB\/00674\/2020"]}]},{"name":"N\u00facleo Regional da Madeira da Liga Portuguesa contra o Cancro (LPCC-NRM)","award":["UIDP\/00674\/2020"],"award-info":[{"award-number":["UIDP\/00674\/2020"]}]},{"name":"N\u00facleo Regional da Madeira da Liga Portuguesa contra o Cancro (LPCC-NRM)","award":["M1420-01-0145-FEDER-000005"],"award-info":[{"award-number":["M1420-01-0145-FEDER-000005"]}]},{"name":"N\u00facleo Regional da Madeira da Liga Portuguesa contra o Cancro (LPCC-NRM)","award":["M1420-09-5369-FSE-000001"],"award-info":[{"award-number":["M1420-09-5369-FSE-000001"]}]},{"name":"N\u00facleo Regional da Madeira da Liga Portuguesa contra o Cancro (LPCC-NRM)","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program","award":["UIDB\/00674\/2020"],"award-info":[{"award-number":["UIDB\/00674\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program","award":["UIDP\/00674\/2020"],"award-info":[{"award-number":["UIDP\/00674\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program","award":["M1420-01-0145-FEDER-000005"],"award-info":[{"award-number":["M1420-01-0145-FEDER-000005"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program","award":["M1420-09-5369-FSE-000001"],"award-info":[{"award-number":["M1420-09-5369-FSE-000001"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Madeira 14-2020 program","award":["M14-20 M1420-01-0145-FEDER-000008"],"award-info":[{"award-number":["M14-20 M1420-01-0145-FEDER-000008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Prostate cancer (PCa) is the most frequently occurring type of malignant tumor and a leading cause of oncological death in men. PCa is very heterogeneous in terms of grade, phenotypes, and genetics, displaying complex features. This tumor often has indolent growth, not compromising the patient\u2019s quality of life, while its more aggressive forms can manifest rapid growth with progression to adjacent organs and spread to lymph nodes and bones. Nevertheless, the overtreatment of PCa patients leads to important physical, mental, and economic burdens, which can be avoided with careful monitoring. Early detection, even in the cases of locally advanced and metastatic tumors, provides a higher chance of cure, and patients can thus go through less aggressive treatments with fewer side effects. Furthermore, it is important to offer knowledge about how modifiable risk factors can be an effective method for reducing cancer risk. Innovations in PCa diagnostics and therapy are still required to overcome some of the limitations of the current screening techniques, in terms of specificity and sensitivity. In this context, this review provides a brief overview of PCa statistics, reporting its incidence and mortality rates worldwide, risk factors, and emerging screening strategies.<\/jats:p>","DOI":"10.3390\/curroncol30020178","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T04:47:24Z","timestamp":1676436444000},"page":"2300-2321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Underlying Features of Prostate Cancer\u2014Statistics, Risk Factors, and Emerging Methods for Its Diagnosis"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-1175","authenticated-orcid":false,"given":"Cristina V.","family":"Berenguer","sequence":"first","affiliation":[{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, NPRG, Campus da Penteada, Universidade da Madeira, 9020-105 Funchal, Portugal"}]},{"given":"Ferdinando","family":"Pereira","sequence":"additional","affiliation":[{"name":"SESARAM\u2014Servi\u00e7o de Sa\u00fade da Regi\u00e3o Aut\u00f3noma da Madeira, EPERAM, Hospital Dr. N\u00e9lio Mendon\u00e7a, Avenida Lu\u00eds de Cam\u00f5es 6180, 9000-177 Funchal, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1965-3151","authenticated-orcid":false,"given":"Jos\u00e9 S.","family":"C\u00e2mara","sequence":"additional","affiliation":[{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, NPRG, Campus da Penteada, Universidade da Madeira, 9020-105 Funchal, Portugal"},{"name":"Departamento de Qu\u00edmica, Faculdade de Ci\u00eancias Exatas e Engenharia, Campus da Penteada, Universidade da Madeira, 9020-105 Funchal, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-5348","authenticated-orcid":false,"given":"Jorge A. M.","family":"Pereira","sequence":"additional","affiliation":[{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, NPRG, Campus da Penteada, Universidade da Madeira, 9020-105 Funchal, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"a030361","DOI":"10.1101\/cshperspect.a030361","article-title":"The Epidemiology of Prostate Cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ucl.2021.03.001","article-title":"Prostate Cancer Predisposition","volume":"48","author":"Bhanji","year":"2021","journal-title":"Urol. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"k3581","DOI":"10.1136\/bmj.k3581","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: A clinical practice guideline","volume":"362","author":"Tikkinen","year":"2018","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/CEJ.0000000000000539","article-title":"Prostate cancer screening in Portugal: Prevalence and perception of potential benefits and adverse effects","volume":"29","author":"Braga","year":"2020","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_8","first-page":"1079","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Center","year":"2012","journal-title":"Liver Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.canlet.2021.11.033","article-title":"The prostate cancer landscape in Europe: Current challenges, future opportunities","volume":"526","author":"Marhold","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and Prevention of Prostate Cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.prnil.2019.08.001","article-title":"A review of social determinants of prostate cancer risk, stage, and survival","volume":"8","author":"Coughlin","year":"2020","journal-title":"Prostate Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41585-018-0006-0","article-title":"Prostate cancer and social media","volume":"15","author":"Loeb","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bju.15699","article-title":"Impact of the COVID-19 pandemic on the diagnosis and treatment of men with prostate cancer","volume":"130","author":"Nossiter","year":"2022","journal-title":"BJU Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2016.09.026","article-title":"Diet, body size, physical activity and risk of prostate cancer: An umbrella review of the evidence","volume":"69","author":"Markozannes","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2018.08.026","article-title":"Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men","volume":"75","author":"Tonon","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"a030387","DOI":"10.1101\/cshperspect.a030387","article-title":"Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood","volume":"8","author":"Rebbeck","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location","volume":"12","author":"Taitt","year":"2018","journal-title":"Am. J. Men\u2019s Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/bjon.2019.28.18.S4","article-title":"The association between ethnic background and prostate cancer","volume":"28","author":"McAllister","year":"2019","journal-title":"Br. J. Nurs."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Brown, C.R., Hambleton, I., Hercules, S.M., Unwin, N., Murphy, M.M., Nigel Harris, E., Wilks, R., MacLeish, M., Sullivan, L., and Sobers-Grannum, N. (2018). Social determinants of prostate cancer in the Caribbean: A systematic review and meta-analysis. BMC Public Health, 18.","DOI":"10.1186\/s12889-018-5696-y"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer USPreventive servicestaskforcerecommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Vietri, M.T., D\u2019Elia, G., Caliendo, G., Resse, M., Casamassimi, A., Passariello, L., Albanese, L., Cioffi, M., and Molinari, A.M. (2021). Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073753"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Brand\u00e3o, A., Paulo, P., and Teixeira, M.R. (2020). Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145036"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ucl.2021.03.008","article-title":"Germline Predisposition to Prostate Cancer in Diverse Populations","volume":"48","author":"Bree","year":"2021","journal-title":"Urol. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/pros.24097","article-title":"Knowledge of prostate cancer among African American men: A systematic review","volume":"81","author":"Coughlin","year":"2021","journal-title":"Prostate"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eururo.2016.08.063","article-title":"Re: Family History and Probability of Prostate Cancer, Differentiated by Risk Category\u2014A Nationwide Population-based Study","volume":"71","author":"Ventimiglia","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1038\/s41467-019-12267-6","article-title":"12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population","volume":"10","author":"Takata","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2016.10.011","article-title":"Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping","volume":"72","author":"Vidal","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103543","DOI":"10.1016\/j.critrevonc.2021.103543","article-title":"Obesity and prostate cancer: A narrative review","volume":"169","author":"Wilson","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Adesunloye, B.A. (2021). Mechanistic Insights into the Link between Obesity and Prostate Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083935"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOU.0000000000000424","article-title":"Obesity and prostate cancer","volume":"27","author":"Bandini","year":"2017","journal-title":"Curr. Opin. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fujita, K., Hayashi, T., Matsushita, M., Uemura, M., and Nonomura, N. (2019). Obesity, Inflammation, and Prostate Cancer. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020201"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-32656-2_1","article-title":"Diet and Lifestyle in Prostate Cancer","volume":"1210","author":"Wilson","year":"2019","journal-title":"Prostate Cancer Cell. Genet. Mech. Dis. Dev. Progress."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/CCO.0000000000000519","article-title":"The evolving role of diet in prostate cancer risk and progression","volume":"31","author":"Kaiser","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2018.07.001","article-title":"Tobacco smoking and survival after a prostate cancer diagnosis: A systematic review and meta-analysis","volume":"70","author":"Darcey","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/07357907.2020.1833212","article-title":"Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy","volume":"38","author":"Sato","year":"2020","journal-title":"Cancer Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.annepidem.2019.08.011","article-title":"Smoking history, intensity, and duration and risk of prostate cancer recurrence among men with prostate cancer who received definitive treatment","volume":"38","author":"Khan","year":"2019","journal-title":"Ann. Epidemiol."},{"key":"ref_37","first-page":"571","article-title":"Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study","volume":"82","author":"Jochems","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2018.1071","article-title":"Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis","volume":"4","author":"Foerster","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10552-020-01279-z","article-title":"Tomato consumption and intake of lycopene as predictors of the incidence of prostate cancer: The Adventist Health Study-2","volume":"31","author":"Fraser","year":"2020","journal-title":"Cancer Causes Control"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"128396","DOI":"10.1016\/j.foodchem.2020.128396","article-title":"Tomato and lycopene and multiple health outcomes: Umbrella review","volume":"343","author":"Li","year":"2021","journal-title":"Food Chem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Soares, N., Elias, M.B., Lima Machado, C., Trindade, B.B., Borojevic, R., and Teodoro, A.J. (2019). Comparative Analysis of Lycopene Content from Different Tomato-Based Food Products on the Cellular Activity of Prostate Cancer Cell Lines. Foods, 8.","DOI":"10.3390\/foods8060201"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Puah, B.P., Jalil, J., Attiq, A., and Kamisah, Y. (2021). New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene. Molecules, 26.","DOI":"10.3390\/molecules26133888"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Oczkowski, M., Dziendzikowska, K., Pasternak-Winiarska, A., W\u0142odarek, D., and Gromadzka-Ostrowska, J. (2021). Dietary Factors and Prostate Cancer Development, Progression, and Reduction. Nutrients, 13.","DOI":"10.3390\/nu13020496"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ijc.31929","article-title":"Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial","volume":"144","author":"Beynon","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s43440-020-00133-y","article-title":"Altered expression of cytochrome P450 enzymes involved in metabolism of androgens and vitamin D in the prostate as a risk factor for prostate cancer","volume":"72","author":"Maksymchuk","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41585-018-0015-z","article-title":"Do dietary calcium and vitamin D matter in men with prostate cancer?","volume":"15","author":"Capiod","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.21873\/anticanres.13977","article-title":"Review of Recent Advances in Understanding the Role of Vitamin D in Reducing Cancer Risk: Breast, Colorectal, Prostate, and Overall Cancer","volume":"40","author":"Grant","year":"2020","journal-title":"Anticancer. Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ardura, J.A., \u00c1lvarez-Carri\u00f3n, L., Guti\u00e9rrez-Rojas, I., and Alonso, V. (2020). Role of Calcium Signaling in Prostate Cancer Progression: Effects on Cancer Hallmarks and Bone Metastatic Mechanisms. Cancers (Basel), 12.","DOI":"10.3390\/cancers12051071"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Applegate, C.C., Rowles, J.L., Ranard, K.M., Jeon, S., and Erdman, J.W. (2018). Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis. Nutrients, 10.","DOI":"10.3390\/nu10010040"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41430-020-0677-5","article-title":"Why has Japan become the world\u2019s most long-lived country: Insights from a food and nutrition perspective","volume":"75","author":"Tsugane","year":"2021","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2174\/1871520619666190404153058","article-title":"The Possibility of Preventive and Therapeutic Use of Green Tea Catechins in Prostate Cancer","volume":"19","author":"Rogovskii","year":"2019","journal-title":"Anticancer. Agents Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Musial, C., Kuban-Jankowska, A., and Gorska-Ponikowska, M. (2020). Beneficial Properties of Green Tea Catechins. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051744"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Miyata, Y., Shida, Y., Hakariya, T., and Sakai, H. (2019). Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer. Molecules, 24.","DOI":"10.3390\/molecules24010193"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.2174\/1381612825666190116124233","article-title":"Cruciferous Vegetables as Antioxidative, Chemopreventive and Antineoplasic Functional Foods: Preclinical and Clinical Evidences of Sulforaphane Against Prostate Cancers","volume":"24","author":"Ferreira","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.canep.2010.11.007","article-title":"Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans","volume":"35","author":"Gunderson","year":"2011","journal-title":"Cancer Epidemiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bjc.2011.273","article-title":"Ethnic differences in prostate cancer","volume":"105","author":"Kheirandish","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Haiman, C.A., Chen, G.K., Blot, W.J., Strom, S.S., Berndt, S.I., Kittles, R.A., Rybicki, B.A., Isaacs, W.B., Ingles, S.A., and Stanford, J.L. (2011). Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1001387"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"560857","DOI":"10.1155\/2013\/560857","article-title":"Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent","volume":"2013","author":"Rebbeck","year":"2013","journal-title":"Prostate Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-06-1049","article-title":"Confirmation of a Positive Association between Prostate Cancer Risk and a Locus at Chromosome 8q24","volume":"16","author":"Suuriniemi","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/pros.21320","article-title":"Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry","volume":"71","author":"Okobia","year":"2011","journal-title":"Prostate"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14068","DOI":"10.1073\/pnas.0605832103","article-title":"Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men","volume":"103","author":"Freedman","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Grammatikopoulou, M.G., Gkiouras, K., Papageorgiou, S., Myrogiannis, I., Mykoniatis, I., Papamitsou, T., Bogdanos, D.P., and Goulis, D.G. (2020). Dietary Factors and Supplements Influencing Prostate Specific-Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials. Nutrients, 12.","DOI":"10.3390\/nu12102985"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Matsushita, M., Fujita, K., and Nonomura, N. (2020). Influence of Diet and Nutrition on Prostate Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041447"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CEJ.0b013e3283647394","article-title":"Dietary factors and risk for advanced prostate cancer","volume":"23","author":"Zhang","year":"2014","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/carcin\/bgn011","article-title":"Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells","volume":"29","author":"Liu","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.7314\/APJCP.2014.15.22.9575","article-title":"Epidemiology, etiology, diagnosis and treatment of prostate cancer","volume":"15","author":"Daniyal","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_68","first-page":"597","article-title":"Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men","volume":"12","author":"Rodriguez","year":"2003","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/aje\/kwp280","article-title":"Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States","volume":"170","author":"Sinha","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1172\/JCI31494","article-title":"Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids","volume":"117","author":"Berquin","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.298.19.2275","article-title":"Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer","volume":"298","author":"Banez","year":"2007","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1940-6207.CAPR-10-0014","article-title":"Obesity, Endogenous Hormone Metabolism, and Prostate Cancer Risk: A Conundrum of \u201cHighs\u201d and \u201cLows\u201d","volume":"3","author":"Kaaks","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2105\/AJPH.2008.150508","article-title":"Smoking as a risk factor for prostate cancer: A meta-analysis of 24 prospective cohort studies","volume":"100","author":"Huncharek","year":"2010","journal-title":"Am. J. Public Health"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.urology.2006.12.020","article-title":"Smoking and Risk of Fatal Prostate Cancer in a Prospective U.S. Study","volume":"69","author":"Rohrmann","year":"2007","journal-title":"Urology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1039\/D1LC00485A","article-title":"The role of liquid biopsies in prostate cancer management","volume":"21","author":"Kim","year":"2021","journal-title":"Lab A Chip"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lima, A.R., Pinto, J., Amaro, F., Bastos, M.d.L., Carvalho, M., and de Pinho, P.G. (2021). Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites, 11.","DOI":"10.3390\/metabo11030181"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu525","article-title":"Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis","volume":"26","author":"Louie","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crad.2019.03.016","article-title":"Prostate biopsy: When and how to perform","volume":"74","author":"Das","year":"2019","journal-title":"Clin. Radiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/pros.22704","article-title":"Metabolomic signatures of aggressive prostate cancer","volume":"73","author":"McDunn","year":"2013","journal-title":"Prostate"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Salciccia, S., Capriotti, A.L., Lagana, A., Fais, S., Logozzi, M., De Berardinis, E., Busetto, G.M., Di Pierro, G.B., Ricciuti, G.P., and Del Giudice, F. (2021). Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094367"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"890697","DOI":"10.1155\/2014\/890697","article-title":"Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up","volume":"2014","author":"Dimakakos","year":"2014","journal-title":"BioMed. Res. Int."},{"key":"ref_83","first-page":"787","article-title":"Prevention of Prostate Cancer Morbidity and Mortality Primary Prevention and Early Detection","volume":"101","author":"Barry","year":"2017","journal-title":"Med. Clin. NA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.urolonc.2012.05.012","article-title":"Defining prostate cancer risk before prostate biopsy","volume":"31","author":"Pal","year":"2013","journal-title":"Urol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12620","DOI":"10.3390\/ijms140612620","article-title":"The present and future of prostate cancer urine biomarkers","volume":"14","author":"Rigau","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-019-0585-4","article-title":"Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine","volume":"121","author":"Lima","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Gaglani, S., Gonzalez-Kozlova, E., Lundon, D.J., Tewari, A.K., Dogra, N., and Kyprianou, N. (2021). Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810131"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tranon.2016.05.004","article-title":"Biomarker Discovery in Human Prostate Cancer: An Update in Metabolomics Studies","volume":"9","author":"Lima","year":"2016","journal-title":"Transl. Oncol."},{"key":"ref_89","first-page":"1309","article-title":"Research landscape of liquid biopsies in prostate cancer","volume":"9","author":"Barcelos","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/s00259-013-2379-x","article-title":"Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry","volume":"40","author":"Spur","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12032-021-01537-3","article-title":"PSMA: A game changer in the diagnosis and treatment of advanced prostate cancer","volume":"38","author":"Parsi","year":"2021","journal-title":"Med. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: Background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cpet.2021.03.004","article-title":"Prostate Cancer Theranostics: PSMA Targeted Therapy","volume":"16","author":"Seifert","year":"2021","journal-title":"PET Clin."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2019.37.7_suppl.228","article-title":"Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer","volume":"37","author":"Hofman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1200\/JCO.2019.37.15_suppl.5028","article-title":"RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer","volume":"37","author":"Calais","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"109893","DOI":"10.1016\/j.ejrad.2021.109893","article-title":"Prostate cancer: Molecular imaging and MRI","volume":"143","author":"Moradi","year":"2021","journal-title":"Eur. J. Radiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00345-020-03344-3","article-title":"Novel PET imaging methods for prostate cancer","volume":"39","author":"Mena","year":"2021","journal-title":"World J. Urol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Thomas, L., Balmus, C., Ahmadzadehfar, H., Essler, M., Strunk, H., and Bundschuh, R.A. (2017). Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET\/CT. Pharmaceuticals (Basel), 10.","DOI":"10.3390\/ph10030068"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"103495","DOI":"10.1016\/j.critrevonc.2021.103495","article-title":"Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: Implications for clinical practice","volume":"167","author":"Oey","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"bqab139","DOI":"10.1210\/endocr\/bqab139","article-title":"Emerging Role of Extracellular Vesicles in Prostate Cancer","volume":"162","author":"Ludwig","year":"2021","journal-title":"Endocrinology"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lorenc, T., Klimczyk, K., Michalczewska, I., S\u0142omka, M., Kubiak-Tomaszewska, G., and Olejarz, W. (2020). Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062118"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-021-01349-z","article-title":"Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer","volume":"20","author":"Ji","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2019.08.010","article-title":"Long non-coding RNAs in prostate cancer: Functional roles and clinical implications","volume":"464","author":"Xu","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.biopha.2018.03.118","article-title":"Long noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer","volume":"102","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/pros.23367","article-title":"Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients","volume":"77","author":"Zhao","year":"2017","journal-title":"Prostate"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Hu, J.C., Wang, S.S., Chou, Y.E., Chiu, K.Y., Li, J.R., Chen, C.S., Hung, S.C., Yang, C.K., Ou, Y.C., and Cheng, C.L. (2021). Associations between LncRNA MALAT1 Polymorphisms and Lymph Node Metastasis in Prostate Cancer. Diagnostics (Basel), 11.","DOI":"10.3390\/diagnostics11091692"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Li, Y., Ji, J., Lyu, J., Jin, X., He, X., Mo, S., Xu, H., He, J., Cao, Z., and Chen, X. (2021). A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study. Cancers (Basel), 13.","DOI":"10.3390\/cancers13164075"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.neo.2021.05.012","article-title":"High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity","volume":"23","author":"Kidd","year":"2021","journal-title":"Neoplasia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/pros.23700","article-title":"Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer","volume":"78","author":"Huang","year":"2018","journal-title":"Prostate"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrurol.2015.182","article-title":"Intrapatient heterogeneity in prostate cancer","volume":"12","author":"Beltran","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Dudka, I., Thysell, E., Lundquist, K., Antti, H., Iglesias-Gato, D., Flores-Morales, A., Bergh, A., Wikstr\u00f6m, P., and Gr\u00f6bner, G. (2020). Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06908-z"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","article-title":"Metastasis and bone loss: Advancing treatment and prevention","volume":"36","author":"Coleman","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_117","first-page":"420","article-title":"New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer","volume":"59","author":"Maffioli","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_118","first-page":"458","article-title":"Molecular radiotheragnostics in prostate cancer","volume":"17","author":"Du","year":"2017","journal-title":"Clin. Med. J. R. Coll. Physicians Lond."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/1878-0261.13071","article-title":"Emerging methods for prostate cancer imaging: Evaluating cancer structure and metabolic alterations more clearly","volume":"15","author":"Retter","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J. Urol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"102864","DOI":"10.1016\/j.critrevonc.2020.102864","article-title":"Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review","volume":"146","author":"Cursano","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","article-title":"The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer","volume":"57","author":"Babich","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","article-title":"The (68)Ga\/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: Correlation of SUV(max) values and absorbed dose estimates","volume":"44","author":"Scarpa","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-018-0683-0","article-title":"Development and Application of Liquid Biopsies in Metastatic Prostate Cancer","volume":"20","author":"Morrison","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.3390\/cancers13133373","article-title":"Prostate Cancer Liquid Biopsy Biomarkers\u2019 Clinical Utility in Diagnosis and Prognosis","volume":"13","author":"Matuszczak","year":"2021","journal-title":"Cancers"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"105.e1","DOI":"10.1016\/j.urolonc.2021.11.012","article-title":"RNA-based biomarkers for the diagnosis, prognosis, and therapeutic response monitoring of prostate cancer","volume":"40","author":"Bae","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_128","first-page":"29","article-title":"Emerging Roles of Long Non-coding RNAs as Novel Biomarkers in the Diagnosis and Prognosis of Prostate Cancer","volume":"32","author":"Kan","year":"2021","journal-title":"Discov. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.critrevonc.2017.11.007","article-title":"Biomarkers in prostate cancer\u2014Current clinical utility and future perspectives","volume":"120","author":"Kretschmer","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"103565","DOI":"10.1016\/j.critrevonc.2021.103565","article-title":"Emerging role of exosomes as biomarkers in cancer treatment and diagnosis","volume":"169","author":"Hanjani","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"102860","DOI":"10.1016\/j.critrevonc.2019.102860","article-title":"Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer","volume":"145","author":"Wang","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021","volume":"80","author":"Roobol","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: A review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_134","first-page":"1","article-title":"Mass spectrometry-based metabolomic profiling of prostate cancer\u2014A pilot study","volume":"5","author":"Arendowski","year":"2019","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"201.e1","DOI":"10.1016\/j.urolonc.2015.02.004","article-title":"Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance","volume":"33","author":"Terracciano","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"18424","DOI":"10.18632\/oncotarget.12906","article-title":"Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance","volume":"8","author":"Ferro","year":"2017","journal-title":"Oncotarget"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer","volume":"4","author":"Hogenhout","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","article-title":"The use of prostate specific antigen density to predict clinically significant prostate cancer","volume":"10","author":"Yusim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/pros.24078","article-title":"Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume","volume":"80","author":"Omri","year":"2020","journal-title":"Prostate"},{"key":"ref_140","first-page":"CD012663","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"6","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Gravina, M., Spirito, L., Celentano, G., Capece, M., Creta, M., Califano, G., Coll\u00e0 Ruvolo, C., Morra, S., Imbriaco, M., and Di Bello, F. (2022). Machine Learning and Clinical-Radiological Characteristics for the Classification of Prostate Cancer in PI-RADS 3 Lesions. Diagnostics (Basel), 12.","DOI":"10.3390\/diagnostics12071565"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s41747-022-00287-9","article-title":"Tasks for artificial intelligence in prostate MRI","volume":"6","author":"Belue","year":"2022","journal-title":"Eur. Radiol. Exp."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41747-022-00288-8","article-title":"Artificial intelligence for prostate MRI: Open datasets, available applications, and grand challenges","volume":"6","author":"Sunoqrot","year":"2022","journal-title":"Eur. Radiol. Exp."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Berenguer, C.V., Pereira, F., Pereira, J.A.M., and C\u00e2mara, J.S. (2022). Volatilomics: An Emerging and Promising Avenue for the Detection of Potential Prostate Cancer Biomarkers. Cancers, 14.","DOI":"10.3390\/cancers14163982"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"bpz014","DOI":"10.1093\/biomethods\/bpz014","article-title":"Digging deeper into volatile organic compounds associated with cancer","volume":"4","author":"Janfaza","year":"2019","journal-title":"Biol. Methods Protoc."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Silva, C., Perestrelo, R., Silva, P., Tom\u00e1s, H., and C\u00e2mara, J.S. (2019). Breast Cancer Metabolomics: From Analytical Platforms to Multivariate Data Analysis. A Review. Metabolites, 9.","DOI":"10.3390\/metabo9050102"},{"key":"ref_147","first-page":"232","article-title":"Urinary metabolites for urological cancer detection: A review on the application of volatile organic compounds for cancers","volume":"7","author":"Gao","year":"2019","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Khalid, T., Aggio, R., White, P., De Lacy Costello, B., Persad, R., Al-Kateb, H., Jones, P., Probert, C.S., and Ratcliffe, N. (2015). Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143283"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpba.2014.12.026","article-title":"Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study","volume":"111","author":"Kordalewska","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clgc.2019.02.003","article-title":"Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer","volume":"17","author":"Gao","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Bax, C., Taverna, G., Eusebio, L., Sironi, S., Grizzi, F., Guazzoni, G., and Capelli, L. (2018). Innovative Diagnostic Methods for Early Prostate Cancer Detection through Urine Analysis: A Review. Cancers (Basel), 10.","DOI":"10.3390\/cancers10040123"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clinms.2020.10.004","article-title":"Analysis of urinary VOCs using mass spectrometric methods to diagnose cancer: A review","volume":"18","year":"2020","journal-title":"Clin. Mass Spectrom."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Tyagi, H., Daulton, E., Bannaga, A.S., Arasaradnam, R.P., and Covington, J.A. (2021). Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers. Biosensors (Basel), 11.","DOI":"10.21203\/rs.3.rs-223926\/v1"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Lima, A.R., Pinto, J., Carvalho-Maia, C., Jer\u00f3nimo, C., Henrique, R., Bastos, M.d.L., Carvalho, M., and Guedes de Pinho, P. (2020). A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers. Cancers, 12.","DOI":"10.3390\/cancers12082017"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Capelli, L., Taverna, G., Bellini, A., Eusebio, L., Buffi, N., Lazzeri, M., Guazzoni, G., Bozzini, G., Seveso, M., and Mandressi, A. (2016). Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review. Sensors (Basel), 16.","DOI":"10.3390\/s16101708"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/178\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:12Z","timestamp":1760121372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/2\/178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":155,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["curroncol30020178"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30020178","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]}}}